GB0212462D0 - Pharmaceutical compound - Google Patents

Pharmaceutical compound

Info

Publication number
GB0212462D0
GB0212462D0 GB0212462A GB0212462A GB0212462D0 GB 0212462 D0 GB0212462 D0 GB 0212462D0 GB 0212462 A GB0212462 A GB 0212462A GB 0212462 A GB0212462 A GB 0212462A GB 0212462 D0 GB0212462 D0 GB 0212462D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical compound
pharmaceutical
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0212462A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to GB0212462A priority Critical patent/GB0212462D0/en
Publication of GB0212462D0 publication Critical patent/GB0212462D0/en
Priority to ES03706732T priority patent/ES2286406T3/en
Priority to DE60332322T priority patent/DE60332322D1/en
Priority to SI200330875T priority patent/SI1480679T1/en
Priority to EP03706732A priority patent/EP1480679B1/en
Priority to AU2003212500A priority patent/AU2003212500B2/en
Priority to DK03706732T priority patent/DK1480679T3/en
Priority to NZ534871A priority patent/NZ534871A/en
Priority to BRPI0308023-4A priority patent/BRPI0308023B1/en
Priority to RU2004129280/15A priority patent/RU2318518C2/en
Priority to IL16364203A priority patent/IL163642A0/en
Priority to IL16368903A priority patent/IL163689A0/en
Priority to EP03708319A priority patent/EP1480650B1/en
Priority to JP2003570883A priority patent/JP4544863B2/en
Priority to CA2476587A priority patent/CA2476587C/en
Priority to MXPA04008330A priority patent/MXPA04008330A/en
Priority to MXPA04008307A priority patent/MXPA04008307A/en
Priority to KR1020107016079A priority patent/KR20100090726A/en
Priority to ES03708319T priority patent/ES2342660T3/en
Priority to JP2003570854A priority patent/JP4836404B2/en
Priority to CA2702297A priority patent/CA2702297C/en
Priority to KR10-2004-7013341A priority patent/KR20040086452A/en
Priority to US10/505,690 priority patent/US7612077B2/en
Priority to NZ534513A priority patent/NZ534513A/en
Priority to BRPI0307786A priority patent/BRPI0307786B8/en
Priority to MYPI20030631A priority patent/MY135609A/en
Priority to PL372215A priority patent/PL208114B1/en
Priority to KR1020047013177A priority patent/KR101002374B1/en
Priority to AU2003208444A priority patent/AU2003208444B2/en
Priority to CNB038046164A priority patent/CN1326569C/en
Priority to US10/505,231 priority patent/US20050163835A1/en
Priority to CNB038091623A priority patent/CN100404032C/en
Priority to CN2007101823970A priority patent/CN101177414B/en
Priority to PCT/GB2003/000794 priority patent/WO2003072108A1/en
Priority to CA2833470A priority patent/CA2833470C/en
Priority to AT03706732T priority patent/ATE362771T1/en
Priority to CA2477350A priority patent/CA2477350C/en
Priority to CN2007101824009A priority patent/CN101177415B/en
Priority to PT03706732T priority patent/PT1480679E/en
Priority to UA20040907788A priority patent/UA76325C2/en
Priority to AT03708319T priority patent/ATE465738T1/en
Priority to PCT/GB2003/000803 priority patent/WO2003072139A1/en
Priority to DE60313956T priority patent/DE60313956T2/en
Priority to TW092103905A priority patent/TWI271193B/en
Priority to UY27682A priority patent/UY27682A1/en
Priority to ARP030100636A priority patent/AR038848A1/en
Priority to SA03240043A priority patent/SA03240043B1/en
Priority to IL163642A priority patent/IL163642A/en
Priority to IL163689A priority patent/IL163689A/en
Priority to IS7420A priority patent/IS2462B/en
Priority to CO04082661A priority patent/CO5601038A2/en
Priority to NO20043866A priority patent/NO328658B1/en
Priority to NO20044047A priority patent/NO329618B1/en
Priority to HK05103350.3A priority patent/HK1070582A1/en
Priority to HK05103383A priority patent/HK1070585A1/en
Priority to CY20071100974T priority patent/CY1108026T1/en
Priority to US12/234,321 priority patent/US20090186890A1/en
Priority to US12/561,835 priority patent/US20100137304A1/en
Ceased legal-status Critical Current

Links

GB0212462A 2002-02-26 2002-05-30 Pharmaceutical compound Ceased GB0212462D0 (en)

Priority Applications (58)

Application Number Priority Date Filing Date Title
GB0212462A GB0212462D0 (en) 2002-05-30 2002-05-30 Pharmaceutical compound
ES03706732T ES2286406T3 (en) 2002-02-26 2003-02-24 PHARMACEUTICAL FORMULATION OF IRESSA THAT INCLUDES A WATER SOLUBLE CELLULOSE DERIVATIVE.
DE60332322T DE60332322D1 (en) 2002-02-26 2003-02-24 NEW CRYSTALLINE SHAPES OF CANCER FIGHTING CONNECTION ZD1839
SI200330875T SI1480679T1 (en) 2002-02-26 2003-02-24 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
EP03706732A EP1480679B1 (en) 2002-02-26 2003-02-24 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
AU2003212500A AU2003212500B2 (en) 2002-02-26 2003-02-24 Novel crystalline forms of the anti-cancer compound ZD1839
DK03706732T DK1480679T3 (en) 2002-02-26 2003-02-24 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
NZ534871A NZ534871A (en) 2002-02-26 2003-02-24 Novel crystalline forms of the anti-cancer compound ZD1839
BRPI0308023-4A BRPI0308023B1 (en) 2002-02-26 2003-02-24 CRYSTALLINE FORM OF COMPOUND, COMPOUND AND PHARMACEUTICAL COMPOSITION
RU2004129280/15A RU2318518C2 (en) 2002-02-26 2003-02-24 Pharmaceutical composition possessing anti-proliferative effect (variants), method for its preparing and methods for its using
IL16364203A IL163642A0 (en) 2002-02-26 2003-02-24 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
IL16368903A IL163689A0 (en) 2002-02-26 2003-02-24 Novel crystalline forms of the anti-cancer compound zd1839
EP03708319A EP1480650B1 (en) 2002-02-26 2003-02-24 Novel crystalline forms of the anti-cancer compound zd1839
JP2003570883A JP4544863B2 (en) 2002-02-26 2003-02-24 Iressa pharmaceutical formulation containing water-soluble cellulose derivative
CA2476587A CA2476587C (en) 2002-02-26 2003-02-24 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
MXPA04008330A MXPA04008330A (en) 2002-02-26 2003-02-24 Novel crystalline forms of the anti-cancer compound zd1839.
MXPA04008307A MXPA04008307A (en) 2002-02-26 2003-02-24 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative.
KR1020107016079A KR20100090726A (en) 2002-02-26 2003-02-24 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
ES03708319T ES2342660T3 (en) 2002-02-26 2003-02-24 NEW CRYSTAL FORMS OF THE ANTICHANCERIGENO COMPOUND ZD1839.
JP2003570854A JP4836404B2 (en) 2002-02-26 2003-02-24 Novel crystal form of anticancer compound ZD1839
CA2702297A CA2702297C (en) 2002-02-26 2003-02-24 Novel crystalline forms of the anti-cancer compound zd1839
KR10-2004-7013341A KR20040086452A (en) 2002-02-26 2003-02-24 Novel crystalline forms of the anti-cancer compound zd1839
US10/505,690 US7612077B2 (en) 2002-02-26 2003-02-24 Crystalline forms of the anti-cancer compound ZD1839
NZ534513A NZ534513A (en) 2002-02-26 2003-02-24 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
BRPI0307786A BRPI0307786B8 (en) 2002-02-26 2003-02-24 pharmaceutical composition, method of preparing the same, methods of inhibiting the rate of precipitation of the agent from solution in the gi tract, and to reduce inter-patient variability with respect to bioavailability and/or plasma concentrations of the agent, and, use of a water-soluble cellulose ether or an ester of a water-soluble cellulose ether
MYPI20030631A MY135609A (en) 2002-02-26 2003-02-24 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
PL372215A PL208114B1 (en) 2002-02-26 2003-02-24 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
KR1020047013177A KR101002374B1 (en) 2002-02-26 2003-02-24 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
AU2003208444A AU2003208444B2 (en) 2002-02-26 2003-02-24 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
CNB038046164A CN1326569C (en) 2002-02-26 2003-02-24 Pharmaceutical formulation of IRESSA comprising a water-soluble cellulose derivative
US10/505,231 US20050163835A1 (en) 2002-02-26 2003-02-24 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
CNB038091623A CN100404032C (en) 2002-02-26 2003-02-24 Novel crystalline forms of the anti-cancer compound ZD1839
CN2007101823970A CN101177414B (en) 2002-02-26 2003-02-24 New crystal form of anti-cancer compound ZD1839, preparation method thereof and medical compound containing the crystal form
PCT/GB2003/000794 WO2003072108A1 (en) 2002-02-26 2003-02-24 Novel crystalline forms of the anti-cancer compound zd1839
CA2833470A CA2833470C (en) 2002-02-26 2003-02-24 Processes for preparing form 1 zd1839 polymorph
AT03706732T ATE362771T1 (en) 2002-02-26 2003-02-24 PHARMACEUTICAL IRESSA COMPOSITION CONTAINING A WATER-SOLUBLE CELLULOSE DERIVATIVE
CA2477350A CA2477350C (en) 2002-02-26 2003-02-24 Novel crystalline forms of the anti-cancer compound zd1839
CN2007101824009A CN101177415B (en) 2002-02-26 2003-02-24 Method for preparing new crystal form of anti-cancer compound ZD1839
PT03706732T PT1480679E (en) 2002-02-26 2003-02-24 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
UA20040907788A UA76325C2 (en) 2002-02-26 2003-02-24 Iressy, drug containing water-soluble cellulose derivative (variants) and method for its manufacture
AT03708319T ATE465738T1 (en) 2002-02-26 2003-02-24 NEW CRYSTALLINE FORMS OF THE CANCER-FIGHTING COMPOUND ZD1839
PCT/GB2003/000803 WO2003072139A1 (en) 2002-02-26 2003-02-24 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
DE60313956T DE60313956T2 (en) 2002-02-26 2003-02-24 PHARMACEUTICAL IRESSA COMPOSITION CONTAINING A WATER SOLUBLE CELLULOSE DERIVATIVE
TW092103905A TWI271193B (en) 2002-02-26 2003-02-25 Pharmaceutical composition comprising 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline or a pharmaceutically-acceptable salt thereof
UY27682A UY27682A1 (en) 2002-02-26 2003-02-26 PHARMACEUTICAL COMPOSITIONS
ARP030100636A AR038848A1 (en) 2002-02-26 2003-02-26 PHARMACEUTICAL COMPOSITION
SA03240043A SA03240043B1 (en) 2002-02-26 2003-03-16 pharmaceutical composition
IL163642A IL163642A (en) 2002-02-26 2004-08-19 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
IL163689A IL163689A (en) 2002-02-26 2004-08-23 Crystalline forms of the anti-cancer compound zd1839, processes for their preparation and pharmaceutical compositions comprising them
IS7420A IS2462B (en) 2002-02-26 2004-08-24 Irresistant formulation containing water-soluble cellulose derivative
CO04082661A CO5601038A2 (en) 2002-02-26 2004-08-24 IRESSA PHARMACEUTICAL FORMULATION THAT INCLUDES A HYDROSOLUBLE CELLULOSE DERIVATIVE
NO20043866A NO328658B1 (en) 2002-02-26 2004-09-15 Pharmaceutical formulation of IRESSA comprising a water-soluble cellulose derivative, preparation thereof, and use thereof
NO20044047A NO329618B1 (en) 2002-02-26 2004-09-24 New crystalline forms of the compound ZD1839, solvate thereof, processes for the preparation thereof and pharmaceutical preparations containing such
HK05103350.3A HK1070582A1 (en) 2002-02-26 2005-04-19 Novel crystalline forms of the anti-cancer compound zd1839
HK05103383A HK1070585A1 (en) 2002-02-26 2005-04-20 Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
CY20071100974T CY1108026T1 (en) 2002-02-26 2007-07-20 IRESSA PHARMACEUTICAL STANDARDIZATION INCLUDING A WATER SOLUTION CELLULAR PRODUCER
US12/234,321 US20090186890A1 (en) 2002-02-26 2008-09-19 Pharmaceutical Formulation of Iressa Comprising a Water-Soluble Cellulose Derivative
US12/561,835 US20100137304A1 (en) 2002-02-26 2009-09-17 Novel crystalline forms of the anti-cancer compound zd1839

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0212462A GB0212462D0 (en) 2002-05-30 2002-05-30 Pharmaceutical compound

Publications (1)

Publication Number Publication Date
GB0212462D0 true GB0212462D0 (en) 2002-07-10

Family

ID=9937694

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0212462A Ceased GB0212462D0 (en) 2002-02-26 2002-05-30 Pharmaceutical compound

Country Status (1)

Country Link
GB (1) GB0212462D0 (en)

Similar Documents

Publication Publication Date Title
GB0218625D0 (en) Pharmaceutical compounds
EG27104A (en) Pharmaceutical compounds
GB0217225D0 (en) Medicinal compounds
GB0225540D0 (en) Medicinal compounds
GB0204719D0 (en) Medicinal compounds
GB0225535D0 (en) Medicinal compounds
GB0220730D0 (en) Medicinal compounds
GB0225030D0 (en) Medicinal compounds
GB0315657D0 (en) Pharmaceutical compounds
GB0215775D0 (en) Pharmaceutical compounds
GB0308511D0 (en) Pharmaceutical compounds
GB0317315D0 (en) Pharmaceutical compounds
GB0206505D0 (en) Pharmaceutical combination
AU2003291642A8 (en) Pyrazoloazepine compounds as pharmaceutical agents
GB0301736D0 (en) Pharmaceutical compounds
GB0313766D0 (en) Pharmaceutical compounds
GB0201520D0 (en) Pharmaceutical uses
PL373409A1 (en) Pharmaceutical combination
GB0204392D0 (en) Pharmaceutical compound
GB0310361D0 (en) Pharmaceutical compound
GB0204391D0 (en) Pharmaceutical compound
GB0212462D0 (en) Pharmaceutical compound
GB0212459D0 (en) Pharmaceutical compound
GB0208248D0 (en) Pharmaceutical compounds
GB0230153D0 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)